Trader consensus assigns an 82.5% probability that no new COVID variant of concern will emerge before 2027, reflecting the stable trajectory of SARS-CoV-2 evolution under active global surveillance. Omicron sublineages such as BA.3.2, XFG, and NB.1.8.1 continue to circulate with notable spike-protein mutations that raise immune-escape possibilities, yet none have triggered higher case rates, severity, or transmission thresholds required for official designation by WHO or ECDC. Wastewater and clinical sequencing through early 2026 show these strains remaining at low prevalence in the United States and Europe, with overall incidence comparable to prior seasons and no strain-replacement events. Routine vaccine updates and established monitoring systems further reduce the likelihood of rapid escalation before the 2027 deadline.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoSí
$238,725 Vol.
$238,725 Vol.
Sí
$238,725 Vol.
$238,725 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Mercado abierto: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus assigns an 82.5% probability that no new COVID variant of concern will emerge before 2027, reflecting the stable trajectory of SARS-CoV-2 evolution under active global surveillance. Omicron sublineages such as BA.3.2, XFG, and NB.1.8.1 continue to circulate with notable spike-protein mutations that raise immune-escape possibilities, yet none have triggered higher case rates, severity, or transmission thresholds required for official designation by WHO or ECDC. Wastewater and clinical sequencing through early 2026 show these strains remaining at low prevalence in the United States and Europe, with overall incidence comparable to prior seasons and no strain-replacement events. Routine vaccine updates and established monitoring systems further reduce the likelihood of rapid escalation before the 2027 deadline.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes